Undeclared muscle relaxants and anti-inflammatory drugs could interact with a patient’s care.
Undeclared muscle relaxants and anti-inflammatory drugs could interact with a patient’s care.
Millions of workers are changing occupations, leading to ripple effects for comp.
Spending and utilization are returning to pre-pandemic levels, with biologics growing in prominence.
The public comment period is underway for this action, which could help with safer drug disposal.
Healthe’s VP of Clinical Services will join a discussion on post-COVID lessons for workers’ comp.
VX-548 delivered significant improvements in pain with few adverse events.
Women workers were more adversely impacted by the pandemic and the recession.
Quest Diagnostics reports increased positivity rates for marijuana in employee drug screenings.
Adults aged 50 and older and immunocompromised individuals may receive a second booster dose.
Nearly 500 stakeholders share their thoughts on industry challenges and priorities.
After a drop in activity due to the pandemic, five states are now considering legislation.
Healthe’s VP of Industry and State Affairs, Sandy Shtab, joined an educational webinar from IAIABC.
Buprenorphine is an opioid used to treat pain, as well as opioid-use disorder.
Legislation could potentially reclassify gig workers as employees entitled to workers’ comp.
Drug advancements surrounding the prevention and treatment of COVID-19.
Since the start of 2022, at least 10 states are considering some form of marijuana legislation.
Healthe’s Director of Product Management talks to Risk & Insurance on how to attract and retain talent in the workers’ comp industry.
The initial results from a collaborative survey between Healthe and Risk & Insurance.®
Phase 3 trials for NVX-CoV2373 across 30,000 people found this vaccine candidate to be safe and effective for the prevention of COVID-19.
New five-day rules are recommended, with variation depending upon vaccination status.
The Bureau of Labor Statistics reports that 4.5 million employees quit their jobs in November 2021.
Healthe’s SVP of Product Strategy and Innovation, Kristine Kennedy, discusses this topic with Risk & Insurance magazine.
Those previously infected by the virus may face long-term health complications.
All adults may now receive a booster shot of any COVID-19 vaccine.
Strategies for a safer, healthier workforce amid COVID-19 and beyond.
All COVID-19 vaccines now have emergency use authorization for a booster dose.
A new migraine medication, various generics, and more.
Long-term health impacts of COVID-19 can complicate claims
Take our survey and share your thoughts on where the industry is headed.
Take part in our virtual speaking sessions at PRIMA and Comp Laude!
The Pfizer vaccine receives full FDA approval, while a new EUA authorizes booster shots for certain populations.
Healthe’s Director of Enterprise Analytics discusses in WorkCompWire how natural language processing can assist with claim review, population management, and more.
Less than 1% of gabapentin prescriptions were prescribed for an FDA-approved diagnosis.
Join our educational session on infectious disease safety in the workplace, and don’t miss a chance to take part in our industry survey!
Healthe’s Director of Product Management explains how centralized data helps claims professionals.
A new WCRI report explores the impact recent opioid legislation has had on injured worker care.
Another WCRI report looks at non-COVID-19 claims with injuries in the first two quarters of 2019 and 2020.
A joint statement announces that at this time, vaccinated adults are protected from the Delta variant.
Extensive isolation and unique stressors may impact the mental health of remote workers.
Changes center around improving the assessment of mental and behavioral impairment.
Connecticut legalizes recreational use, and NCCI expects even more states to follow suit.
Join our VP of Clinical Services on July 29th for a discussion on care and program considerations for underrepresented populations.
Wegovy (semaglutide) and sotrovimab will soon be available.
How to leverage the patient’s influence over care outcomes.
A new flash report from the WCRI highlights trends in drug utilization.
Corrections officers in Nebraska benefit from a new law; will healthcare workers in Connecticut join them?
Check out Healthe’s latest featured article with WorkCompWire
Join our VP of Clinical Services on July 15th for a discussion on underrepresented populations in workers' comp.
Due to mutating viral strains, the potential benefits of this COVID-19 drug no longer outweigh the risks.
While many states are making decisions regarding gig workers, federal action could soon change things.
After reviewing six rare cases of blood clots after 7 million doses, current data indicates the vaccine is safe.
More states consider allowing injured workers to choose their treating physician.
Join Healthe’s Heather Stempien and Sandy Shtab for a panel presentation with IAIABC on April 28th!
Over 600 stakeholders shared their thoughts on top industry challenges.
Among 1,600 emergency department workers, 46% had burnout symptoms.
Both State Supreme Courts ruled in favor of reimbursement.
A novel bupivacaine formulation works as a 72-hour local anesthetic following shoulder surgery.
Healthe leaders share their thoughts with Risk & Insurance®
New data from a safety trial creates concern surrounding the rheumatoid arthritis drug.
State-led efforts to combat the drug price issue continue to emerge across the nation.
Healthe’s AVP of Advocacy & Compliance will provide guidance on workers’ comp regulations.
Join us for a panel discussion on March 10th as part of the NWCDC Digital Session Series.
Kristine Kennedy, SVP of Product Strategy and Innovation, talks to Risk & Insurance®
The Department of Labor issued a new rule while special interest groups push for regulatory change.
Alleged violations of the Controlled Substances Act could result in billions of dollars in penalties.
Initial insights from Healthesystems’ annual industry survey.
Vaccine candidates from Pfizer-BioNTech and Moderna received EUAs, as did the first at-home test that delivers results in 30 minutes, and two treatments for the virus.
Navigating the workers’ comp process can be daunting for patients, and empathy can go a long way in improving outcomes.
A new report explores how COVID-19 has impacted telemedicine, as well as opportunities for expansion.
Healthesystems’ Chief Medical Officer comments on the U.S. House’s approval of marijuana decriminalization.
Veklury is approved for hospitalized patients, while bamlanivimab is being investigated in mild-to-moderate cases of COVID-19.
Across the nation, not only is marijuana growing more accepted, but so are other drugs like psilocybin and MDMA.
Direct customer exposure is associated with a five-fold risk of infection, while less social distancing in the workplace is tied to depression and anxiety.
The election saw passage of a measure to exempt rideshare drivers from employee status, impacting benefits and more.
Even at recommended doses, benzodiazepine use can lead to misuse, abuse, and addiction.
User research indicates that patients face difficulty with the intake process, getting key claim information, and more.
The drug manufacturer is pleading guilty and paying out billions.
With the pandemic disrupting the healthcare system, how has workers’ comp been impacted?
The FDA recommends healthcare professionals co-prescribe the opioid overdose reversal drug with all opioid prescriptions.
Healthesystems’ VP of Clinical Services addresses COVID-19 disruptions to workers’ comp, along with helpful strategies
AMA hopes to shift from a crisis-reaction framework to a more holistic model that prevents overdose while helping pain patients receive care.
As complex claims continue to impact workers’ comp, our new article in WorkCompWire addresses the need for early warnings and clinical guidance.
Subcutaneous injections of the new biologic, adalimumab-fkjp, were approved for seven indications.
Strategies for anticipating and mitigating complex claim risks.
The AMA suggests that prescription medications are no longer a significant factor in the opioid epidemic, and that opioid prescription limits should change.
Data from 28 states years found that NSAIDs and dermatological agents are seeing growth in spending.
The malaria drug loses an EUA for COVID-19, while the FDA warns of drug interactions that can reduce antiviral effectiveness.
With opioid utilization decreasing, what concerns do other pain therapies pose?
Occupations are divided into risk categories where each category must utilize appropriate face coverings, masks, or respirators.
The National Safety Council discusses managing employee anxiety stemming from COVID-19 when returning to work.
How comorbidities, fatigue, and mental health impact claims management.
A new study explores patients’ use of health services, the impact on medicine use, research activity, and more.
Many states expanded workers’ comp for COVID-19, but California casts a wider net.
Healthesystems’ AVP of Advocacy & Compliance discusses regulatory action related to COVID-19 with WorkCompWire.
With frontline workers at risk, states are expanding coverage to healthcare workers, first responders, and other frontline workers.
Healthesystems’ VP of Clinical Services discusses population trends, non-opioid pain therapies, and comorbidities with WorkCompWire.
A study of 41,000 adults finds that only treatment with buprenorphine or methadone reduced risk of overdose.
A new seizure drug has been approved, and a nerve growth drug advances in clinical trials.
Testing positive for marijuana use could one day no longer prohibit employment.
According to the CWCI, reduced opioid utilization from 2010-2017 saved $6.5 billion in California comp costs.
How more dynamic data can illuminate program performance to empower care delivery
The guideline covers a wide range of relevant topics, including pain, dosing, dangerous co-prescribing, comorbidities, and more.
Shortly after California made strides on employee classification for gig economy jobs, New Jersey and New York have taken action.
Indicated for various gastrointestinal concerns, these recalls could impact certain workers’ comp patients.
A new white paper explores clinical, legislative, workplace safety, and PBM considerations surrounding marijuana.
This reclassification will entitle millions of workers to benefits previously withheld, including workers’ comp.
Healthesystems’ clinical leaders speak to mitigation strategies to reduce workplace injuries stemming from fatigue.
The utilization of opioids, compounds, and physician-dispensed medications have significantly decreased.
An Oklahoma judge found the drug maker to be partially responsible for the harm of the opioid epidemic.
Sandy Shtab has been recognized for making significant contributions to the workers’ comp industry.
While many states report fewer opioid prescriptions, MME levels vary more significantly by state.
Generic versions of Ultram (tramadol hydrochloride) tablets and Dyloject (diclofenac sodium) injections have been approved by the FDA.
While the utilization of opioids and other problematic drugs decreased, similar drops were seen in states without closed formularies.
Stephanie Arkelian has been recognized as a talented young professional making a positive impact on the workers’ comp industry.
Beyond exceptions for safety or federal positions, employers cannot refuse employment for testing positive for marijuana in pre-employment drug screenings.
A new study builds upon earlier research with a larger, more up-to-date dataset, finding a reversal in trends.
Orphengesic Forte has received a decision date of August 14, 2019.
How services like Lyft and Uber can amplify injured worker transportation programs to improve claims outcomes.
Though they’re only needed for special cases in workers’ comp, anticancer medications can easily exceed $10,000 per monthly fill.
Though most forms of marijuana are highly regulated, CBD products are readily available across the country. What does this mean for healthcare?
In a call for public comment, the FDA believes that reducing excess opioid supplies can lower opioid misuse, abuse, and overdose.
The life saving antidote for opioid overdose will soon be available in a consumer-friendly, generic nasal spray.
Combining all three drugs can reduce claim closure rates to 58.3%, with average claim costs of $94,000.
Florida enacted a law to cover 21 different cancers, while other states like Montana, Maryland, and Virginia have recently passed similar laws.
Four research sites will test proven opioid prevention and treatment interventions, hoping to reduce overdose deaths by 40% over three years.
New changes to REMS safety programs will require stronger treatment documentation and oversight.
Patient engagement can lead to better health outcomes, but not all engagement strategies are equally effective.
Various state and local governments have sued drug developers for the harms of the opioid epidemic, and this could be the first of many settlements.
Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.
Demographic factors such as gender, ethnicity, socioeconomic status, age, and location can impact opioid risks.
Can special implants in the brain override paralysis? The FDA believes one day they could.
The FDA created special drug labels to clear a development hurdle and encourage manufacturers.
A new JAMA study finds that increased county-level opioid marketing was tied to elevated overdose mortality.
An analysis of 90,000 private claims explores the relationship between early PT and reduced long-term opioid use in musculoskeletal pain.
The reSET-O app uses cognitive behavioral therapy techniques to assist patients engaged in medication-assisted therapy for opioid dependence.
Formulary and claims management considerations for populations at risk for “mental-only” cases of PTSD.
Dr. Silvia Sacalis of Healthesystems teamed up with Dr. Adam Seidner of The Hartford for a session at NWCDC – here are 5 key takeaways.
A study of 9,596 claimants who filled an opioid prescription found that 30% were still taking opioids 90 days later.
Healthesystems’ VP of Clinical Services offers insight into prescriptions in workers’ comp claims that should raise concerns.
Assembly No. 4505 may solidify precedence recently made by a judge from the Division of Workers’ Compensation.
Common risk factors can increase worker fatigue, leading to more frequent workplace injuries and a loss of productivity.
Cassipa (buprenorphine and naloxone) sublingual film delivers a new dosage for the treatment of opioid dependence.
Healthesystems’ VP of Clinical Services explains how too many drugs in a claim can cause health concerns, and what can be done to prevent them.
On average, construction workers are six times more likely to die from an opioid overdose death, more than any other occupation.
Healthesystems’ Chief Medical Officer spoke with WorkCompCentral regarding DEA plans to reduce opioid manufacturing.
NKTR-181 is supposed to offer a lower frequency of opioid side effects. But are more opioids really the solution we need to the opioid crisis?
Healthesystems’ AVP of Advocacy & Compliance explains how regulation has been unable to keep pace with healthcare innovation & technology.
Drugs to treat opioid dependence could be approved under new clinical endpoints other than reducing opioid use.
Phase 2/3 clinical trial results for Korsuva demonstrate pain relief with fewer side effects.
Millennials are more diverse and more open to alternative therapies, medical marijuana, healthcare technology, and dialogue surrounding psychosocial concerns.
A flurry of recent developments continues to bring the medical marijuana debate front and center, including further legalization, a Senate bill, a drug approval, and more.
In a randomized clinical trial of 460 patients, researchers found the treatment to have similar impact on self-rated disability as standard wound dressing.
Among many findings, JAMA reports that 20% of deaths among those aged 25-34 were opioid-related.
Our Chief Medical Officer and VP of Clinical Services comment on the clinical use of ecstasy and marijuana.
A newly released draft guidance encourages the development of more sustained-release buprenorphine products.
Senate Bill 336 passed with a 44-6 vote and is now headed to the House.
In a special partner post with WorkCompWire, Healthesystems discusses developments in pain management, specialty drugs, and more.
Healthesystems’ VP of Clinical Services discusses how workers’ comp is embracing a value-driven approach.
Healthesystems' VP of Clinical Services will co-present Workers' Comp Opioid Use Trends and Effective Population Health Management
The number of opioid-dependent injured workers in the Ohio workers' comp system fell 19% in 2017.
Forty-one states and over 200 cities and counties claim drug makers deceived patients and doctors regarding opioid safety and addiction risks.
The passage of opioid action plans in Arizona, Tennessee, and Pennsylvania are the most recent additions to growing statewide efforts to curb the epidemic.
The Department of Justice’s recent announcement may come to a head with the will of state governments and popular opinion.